In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of
intralesional injection of a modified human herpes simplex virus and systemic anti-PD-1
treatment resulted in a 62% response rate in patients with metastatic melanoma,
accompanied by enhanced T cell infiltration in virus-injected lesions.